Loading...
•
Dec 31, 2024
Xeris Biopharma Q4 2024 Earnings Report
Xeris Biopharma reported record Q4 2024 revenue, achieving strong growth and positive cash flow while maintaining a disciplined financial strategy.
Key Takeaways
Xeris Biopharma reported a record Q4 2024 with total revenue of $60.10 million, reflecting a 35.4% year-over-year increase. Net loss improved significantly to $5.11 million from $13.39 million in Q4 2023. The company generated positive cash flow of $2 million and posted an Adjusted EBITDA of $8.3 million. Strong growth in Recorlev, which saw a 131% YoY increase in revenue, contributed significantly to the performance. The company ended the quarter with $71.62 million in cash, maintaining a strong financial position.
Q4 2024 revenue reached $60.10 million, a 35.4% YoY increase.
Net loss narrowed to $5.11 million from $13.39 million in Q4 2023.
Adjusted EBITDA improved to $8.3 million in Q4 2024.
Cash and cash equivalents stood at $71.62 million at quarter-end.
Xeris Biopharma
Xeris Biopharma
Xeris Biopharma Revenue by Segment
Revenue by Segment
Recorlev Revenue
CapyFin.comGvoke Revenue
CapyFin.comKeveyis Revenue
CapyFin.com Forward Guidance
Xeris Biopharma expects continued revenue growth in 2025, with total revenue projected between $255 million and $275 million, representing over 30% growth at the mid-point. Adjusted EBITDA is expected to remain positive.
Positive Outlook
- 2025 revenue projected to grow over 30% at the mid-point.
- Continued strong growth expected in Recorlev and Gvoke sales.
- Company maintains a disciplined financial strategy with positive EBITDA.
- Pipeline advancements, including XP-8121 for hypothyroidism, progressing.
- Strong liquidity position with over $71M in cash to support future growth.
Challenges Ahead
- Keveyis revenue declined by 21% in Q4 2024 due to lower product shipments.
- Ongoing investments in commercialization and R&D could impact short-term profitability.
- Competition in the biopharma space remains a risk to revenue growth.
- Regulatory and reimbursement uncertainties could affect future sales.
- Higher operating costs expected due to expansion of commercial operations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income